Showing results (11-20 of 1,152) with videos related to
Sort By:
Pageof 116
Gastrointestinal Endoscopy Clinics of North America|October 1, 1996
Pharmacologic therapy of arteriovenous malformationsE Van Cutsem, H PiessevauxAnnals of Oncology : Official Journal of the European Society for Medical Oncology|July 14, 2005
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitorsS Segaert, E Van CutsemBulletin Du Cancer|February 5, 1999
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]E Van Cutsem, M PeetersDrugs of Today (Barcelona, Spain : 1998)|February 28, 2004
Molecular defects in colorectal tumorigenesisS Tejpar, E van CutsemColorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|April 11, 2013
The role of oxaliplatin in the management of upper gastrointestinal tract malignanciesW Scheithauer, E Van CutsemCurrent Opinion in Oncology|July 23, 1999
Developments in fluoropyrimidine therapy for gastrointestinal cancerE Van Cutsem, M PeetersJournal Belge De Radiologie|January 1, 1991
Epidemiology and clinical aspects of esophageal cancerE Van Cutsem, G VantrappenBritish Journal of Cancer|January 10, 2013
Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancerD Cunningham, R P W Wong, G D'Haens, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trialsE Mitry, J-Y Douillard, E Van Cutsem, et al.Seminars in Oncology|April 23, 1999
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study GroupE Van Cutsem, G H BlijhamPageof 116